Skip to main content

Advertisement

SpringerLink
Log in

Opportunities for Neuroprotective Drugs in the Era of Vascular Recanalization

  • Comment
  • Published:
Translational Stroke Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data Availability

Not applicable.

References

  1. Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, Abbasifard M, Abbasi-Kangevari M, Abd-Allah F, Abedi V, Abualhasan A. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820.

    Article  CAS  Google Scholar 

  2. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59(3):467–77.

    Article  CAS  PubMed  Google Scholar 

  3. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, Sarraj A, Kasner SE, Ansari SA, Yeatts SD, Hamilton S, Mlynash M, Heit JJ, Zaharchuk G, Kim S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378(8):708–18.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, Sila CA, Hassan AE, Millan M, Levy EI, Mitchell P, Chen M, English JD, Shah QA, Silver FL, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21.

    Article  PubMed  Google Scholar 

  5. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Dávalos A, Majoie CB, van der Lugt A, de Miquel MA, Donnan GA, Roos YB, Bonafe A, Jahan R, Diener HC, van den Berg LA, Levy EI, Berkhemer OA, Pereira VM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet (London, England). 2016;387(10029):1723–31.

    Article  PubMed  Google Scholar 

  6. Liu S, Liu W, Ding W, Miyake M, Rosenberg GA, Liu KJ. Electron paramagnetic resonance-guided normobaric hyperoxia treatment protects the brain by maintaining penumbral oxygenation in a rat model of transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2006;26(10):1274–84.

    Article  CAS  Google Scholar 

  7. Liang J, Qi Z, Liu W, Wang P, Shi W, Dong W, Ji X, Luo Y, Liu KJ. Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia. Stroke. 2015;46(5):1344–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, Lo EH, Buonanno FS, Gonzalez RG, Sorensen AG. A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke. 2005;36(4):797–802.

    Article  PubMed  Google Scholar 

  9. Shi SH, Qi ZF, Luo YM, Ji XM, Liu KJ. Normobaric oxygen treatment in acute ischemic stroke: a clinical perspective. Med Gas Res. 2016;6(3):147–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Li W, Qi Z, Ma Q, Ding J, Wu C, Song H, Yang Q, Duan J, Liu L, Kang H, Wu L, Ji K, Zhao W, Li C, Sun C, Li N, Fisher M, Ji X, Liu KJ. Normobaric hyperoxia combined with endovascular treatment for acute ischemic stroke patients: a randomized controlled clinical trial. Neurology. 2022;99(8):e824–34.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was supported by grants from the National Natural Science Foundation of China (82271308) and Beijing Natural Science Foundation (7222080).

Author information

Authors and Affiliations

  1. Department of Neurology, Beijing Institute for Brain Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China

    Zhifeng Qi

  2. Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, 11794, NY, USA

    Ke Jian Liu

  3. Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA

    Ke Jian Liu

Authors
  1. Zhifeng Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ke Jian Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ZQ and KJL discussed, conceptualized, and wrote this commentary. Both authors reviewed the manuscript.

Corresponding author

Correspondence to Ke Jian Liu.

Ethics declarations

Ethical Approval

Not applicable.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qi, Z., Liu, K.J. Opportunities for Neuroprotective Drugs in the Era of Vascular Recanalization. Transl. Stroke Res. 15, 333–334 (2024). https://doi.org/10.1007/s12975-023-01128-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12975-023-01128-6

Search

Navigation